34 results about "Flavanonol" patented technology

The invention discloses a method for increasing proanthocyanidin content in escherichia coli by cotransformation of brassica juncea gene BAN and DFR. According to the invention, an anthocyanidin reductase BAN gene and a 4-flavanonol reductase DFR gene are cloned from cDNA of brassica juncea purple-leaf mustard seed coat; a prokaryotic expression vector pET-BAN-DFR containing the BAN and DFR genesis constructed; and the BAN and the DFR genes are introduced into DH5alpha escherichia coli simultaneously. The transformed strain is cultured in an LB liquid medium at 25-37 DEG C at 150-250 rpm for6-12 hours, then cultured under shaking in an LB liquid medium containing black soybean seed coat extracts (0.5-1.0 g / L) at 25-37 DEG C at 150-250 rpm for 36-54 hours; the strain is collected by centrifugation; and the proanthocyanidin content in escherichia coli is determined by a DMACA-HCl method. The transgenic escherichia coli obtained in the invention has significantly increased proanthocyanidin content, and the maximum content can be 19.8 times higher than that of a non-transformed control strain.

The invention relates to a novel 5, 6, 7- tri-oxygen Dihydroflavonol, shown in formula (1), the preparation method and its application. The compound can be used to prepare drug combination that can prevent hepatitis b, protect liver, treat fungal infection, prevent diseases that generates free radical during disease change including inflammation, autoimmune diseases, radiotherapy sequela, tumor, myocardial ischemia, cardiac hypertrophy, aging, allergic reaction and atherosclerosis. There are various preparations for said drug combination.

The invention relates to application of B-ring ethyoxyl flavanonol in preparing medicaments for treating hepatitis B viruses, in particular to application of a compound as shown in a formula (1) or a medicinal salt thereof in preparing medicaments for clearing away hepatitis B virus surface antigens (HBsAg) and hepatitis B e-antigen (HBeAg) and medicaments for inhibiting the duplication of hepatitis B virus desoxyribonucleic acid (HBV DNA). The compound or the medicinal salt thereof has extremely obvious activity on inhibiting the HBsAg and the HBeAg, and in the presence of a concentration of20 microgram / milliliter, the intensities for clearing away the HBsAg and the HBeAg of the compound or the medicinal salt thereof are respectively 99.8 percent and 48.5 percent and are 6.2 times and 2.7 times of that of alpha-interferon which is a positive control medicament. More importantly, in the presence of the concentration, the inhibition ratio of the compound or the medicinal salt thereof to the HBV DNA is 64.7 percent, and the activity is 1.7 times of that of the alpha-interferon. Accordingly, the flavone lignan or the medicinal salt thereof can be expected to be used for preparing non-nucleoside medicaments for treating infectious diseases of the hepatitis B viruses.

The invention relates to application of flavanonol lignanoid in preparing an antiviral hepatitis B medicine, in particular to application of angle flavanolignan or pharmaceutically acceptable salts thereof in preparing a medicine which can be used for eliminating hepatitis B e antigen HBeAg, inhibiting HBV DNA replication and treating hepatitis B virus infection diseases. The flavanolignan has a certain HBeVg activity inhibition, the HBeAg elimination intensity of the flavanolignan is higher than that of a positive control first-line medicine as lamivudine in light concentration and is equivalent to that of alpha-interferon of 1000 unit / ml, and meanwhile, under the concentration of 20 microgram / ml, the flavanolignan displays an inhibition ratio which is larger than 45 percent for HBV DNA.The pharmacodynamics result indicates the application of the flavanolignan or the pharmaceutically acceptable salts thereof in preparing the medicine as expected for eliminating hepatitis B e antigen, inhibiting HBV DNA replication and treating hepatitis B virus infection diseases.

The invention relates to application of lignin flavanonol in preparation of antiviral drugs, particularly, the invention relates to a chemical compound as formula (I), (+-)-2-[2,3-dihydro-2-(3,5-dimethoxy-4-hydroxy phenyl)-3-hydroxymethyl-1,4-benzodioxane-5]-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyrone-4-ketone, or use of its medicinal salt used for preparing drugs for repressing virus infectioncaused by herpes simplex virus HSV-1 and / or drugs for curing oral ulcer. The chemical compound is prepared by chemical synthesis, pharmacological experiments shows that, the chemical compound has powerful inhibitory action to the herpes simplex virus HSV-1, and the half inhibitory concentration value IC[50] is 39.41 mg / mL.

The present invention refers to the technical field of flavone component extraction, and provides an extraction separation method of a flavone component based on amination graphene. The flavone components comprise flavones, flavanols, isoflavones, flavanones, flavanonols, flavanones, anthocyanidins, chalcones, and chromones etc. The extraction separation method is adsorption extraction, and amination graphene is taken as a medium of adsorption extraction. The extraction separation method of the flavone components based on amination graphene is superior in separation speed and product purity, low cost and convenient operation.

The invention relates to a method for extracting 3,4',7-trihydroxy flavanonol and fustin with the antioxidant activity from varnish tree wood meal, and belongs to the field of development and application of plant extracts and chemistry of natural products. The varnish tree wood meal is used as a raw material, extraction, silica gel column chromatography and middle-lowerpressure chromatography are performed to obtain the 95% or above 3,4',7-trihydroxy flavanonol and fustin. The ingredients with the efficient antioxidant activity are obtained from a varnish tree, and the removal rate of DPPH, ABTS and hydroxyl radicals is higher than 95% when the concentration is 50 mg / L or above. The preparation process is rapid and simple, the extracted 3,4',7-trihydroxy flavanonol and fustin are good sources for developing a potential natural antioxidant, and the good commercial prospect is achieved.

The present invention has an object to provide an agent for strengthening calcium-containing tissues, which can be safely applied; and its use: The present invention solves the object by providing an agent for strengthening calcium-containing tissues, which comprises one or more flavones, flavonols, flavanones, flavanonols, anthocyanidins, flavanols, chalcones, and aurones.